| Trail of Red Alerts For
Baxter's Vaccine Practices
EU
agency recommends Baxter's H1N1 flu shot 02 Oct 2009 European
drugs regulators recommended Baxter's Celvapan vaccine 'against'
H1N1 flu for approval on Friday and said it expected the shot
to get a licence from the European Commission "shortly".
The recommendation from the European Medicines Agency (EMEA) comes
after its expert committee on new drugs also gave a green light
last week to the first H1N1 swine flu vaccines from GlaxoSmithKline
and Novartis, called Pandemrix and Focetria.
Baxter
not to provide anti-swine flu vaccine to Czechs --Czech Health
Ministry: Baxter unable to guarantee its vaccine is safe, won't
be responsible for its side-effects 03 Aug 2009 The U.S. pharmaceutical
firm Baxter which manufactures a vaccine against the swine flu
in its Czech branch will not ensure the vaccine for the Czech
Republic in the case of a pandemic, Baxter media representative
Jana Cechova told CTK today. "No contract for the delivery
of the vaccines A(H1N1) between Baxter and the Czech Republic
has been concluded," Cechova said. The server tn.cz writes
that the Czech Health Ministry has explained its stopping the
talks with Baxter by the firm's inability to guarantee that the
vaccine is safe and who will bear the risks for possible side-effects.
Barack Opharma issues the ultimate bad news during his weekly
Friday night bad news dump: Legal
immunity set for swine flu vaccine makers 17 Jul 2009 The
last time the government embarked on a major vaccine campaign
against a new swine flu, thousands filed claims contending they
suffered side effects [paralysis, death] from the shots. This
time, the government has already taken steps to head that off.
Vaccine makers and federal officials will be immune from lawsuits
that result from any new swine flu vaccine, under a document signed
by Secretary of Health and Human Services Kathleen Sebelius, government
health officials said Friday. The document signed by Sebelius
last month grants immunity to those making a swine flu vaccine,
under the provisions of a 2006
law for public health emergencies.
Baxter
Files Swine Flu Vaccine Patent a Year Ahead of Outbreak --US20090060950A1
to Baxter International filed 28th August 2008 By Lara 10 Jul
2009 Baxter Vaccine Patent Application US
2009/0060950 A1 --'In particular preferred embodiments the
composition or vaccine comprises more than one antigen.....such
as influenza A and influenza B in particular selected from of
one or more of the human H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2,
H7N2, H7N3, H10N7 subtypes, of the pig flu H1N1, H1N2, H3N1 and
H3N2 subtypes, of the dog or horse flu H7N7, H3N8 subtypes or
of the avian H5N1, H7N2, H1N7, H7N3, H13N6, H5N9, H11N6, H3N8,
H9N2, H5N2, H4N8, H10N7, H2N2, H8N4, H14N5, H6N5, H12N5 subtypes.'
Baxter
can take no more H1N1 flu vaccine orders 16 Jul 2009 While
at least 50 governments have placed orders or are negotiating
with drug companies for supplies of flu vaccine against the [their]
fast spreading H1N1 strain, the lone U.S.-based maker has already
taken on as much as it can handle. Baxter International Inc said
on Thursday it has taken orders from five countries, including
Britain, Ireland and New Zealand, for a total of 80 million doses
of H1N1 vaccine and will not take any more.
'Clearly we believe this demand has the potential to translate
into a significant opportunity.' Baxter
2Q Profit Up 7.9%; Full-Year Guidance Raised 16 Jul 2009 Baxter
International Inc. posted a stronger-than-expected 7.9% rise in
second-quarter profit with help from improved margins and product
sales that continued to avoid any hits from the economic downturn.
The medical-products maker boosted its 2009 earnings guidance
while saying the increase doesn't reflect at this point any contribution
from making a vaccine for the H1N1 flu strain. Baxter reported
a second-quarter profit of $587 million, or 96 cents a share,
up from $544 million, or 85 cents a share, a year earlier.
Human
trial of swine flu vaccine 'soon' 15 Jul 2009 The federal
government has defended its policy of not following the United
Kingdom's lead and rushing out a swine flu vaccine. Biopharmaceutical
company CSL will start clinical vaccine trials on 240 healthy
adults in Adelaide next week. The vaccine is due to be rolled
out in October.
Baxter
working on vaccine to stop swine flu, though admitted sending
live pandemic flu viruses to subcontractor By Lori Price 26 Apr
2009 The OMFG moment of the century: Illinois-based Baxter
working on vaccine to 'stop' swine flu outbreak in Mexico 25 Apr
2009 Specialty drug maker Baxter International Inc. will work
with the World Health Organization to develop a vaccine that could
stem [foment] an outbreak of a deadly swine flu strain in Mexico.
Baxter spokesman Christopher Bona said Saturday that the Deerfield,
Ill.-based company has asked the WHO for a sample of the flu strain.
He says Baxter has patented technology that allows the company
to develop vaccines in half the time it usually takes -- about
13 weeks instead of 26.
Baxter
admits sending live avian flu viruses to subcontractor --Baxter
admits contaminated seasonal flu product contained live bird flu
virus 27 Feb 2009 The company that released contaminated flu virus
material from a plant in Austria confirmed Friday that the experimental
product contained live H5N1 avian flu viruses. And an official
of the World Health Organization's European operation said the
body is closely monitoring the investigation into the events that
took place at Baxter International's research facility in Orth-Donau,
Austria.
Reference Sources: www.legitgov.org
October 6, 2009
 ...............................................................................................................
|
